Associate Director / Director of Product Management, Signatera Hematologic Oncology (Heme)

Position Summary: Natera is a global leader in cell-free DNA testing, focused on changing the management of disease in reproductive health, oncology, and organ transplantation. Signatera is a personalized, tumor-informed test for molecular residual disease (MRD) assessment and surveillance monitoring in patients previously diagnosed with cancer. The Associate Director / Director of Product Management, Signatera Heme will own the product strategy and roadmap for Signatera in hematologic malignancies, starting with multiple myeloma and lymphomas. This person will work in a highly matrixed environment with the Foresight BU, R&D, Lab Operations, Software Engineering, Medical Affairs, Marketing, Business Development, and Regulatory. The role combines product management, market entry as a laboratory developed test (LDT), evidence generation, analytics, and clinical trial product support, including trials run under IUO and IVD pathways. Primary Responsibilities:

Develop and execute the Signatera product roadmap for hematologic malignancies, beginning with multiple myeloma and lymphomas (for example, DLBCL, follicular, mantle cell, and Hodgkin lymphoma) and extending to additional heme indications. Lead market entry planning for Signatera in heme as a laboratory developed test (LDT), including clinical validation requirements, CLIA and state requirements, market access/reimbursement and payer considerations, and launch readiness with Lab Operations, Regulatory, Medical, commercial and Marketing. Define product requirements for blood-based malignancies with R&D, Lab Operations, and Software Engineering, including assay, sample type, workflow, and reporting needs. Lead product support for clinical trials using Signatera in heme, including IUO use in studies with pharma and academic partners, and the path toward IVD and regulated use. Partner with Regulatory, Clinical, and Business Development on trial start-up, study requirements, and pharma and companion diagnostic opportunities. Build product performance metrics and dashboards. Analyze test volume, adoption, ordering patterns, turnaround time, and retention. Use the results to prioritize improvements. Partner with Medical Affairs and Clinical on evidence generation strategy and execution. Areas of collaboration include identifying clinical gaps, designing studies, working with investigators and trial partners, and planning publications and congress presentations. Guide product development for Signatera Genome in heme, including whole genome sequencing technology, phased variants, and structural variants. Work with R&D and Bioinformatics to define how these features improve tumor tracking and MRD sensitivity in heme malignancies. Conduct Voice of Customer interviews, market research, and competitive and market intelligence in hematologic oncology. Engage with key opinion leaders, advisory boards, and congresses (for example, ASH, EHA, and ASCO). Gather insights to guide product decisions. Work with Marketing on product positioning, launch plans, pricing, and key collateral. Build business cases and financial models to support product initiatives. Present strategy, progress, and data-driven recommendations to executive leadership. Performs other duties as assigned.

Qualifications:

Bachelor’s degree in life sciences, statistics, engineering, or a related field. Advanced degree (MS, PhD, or MBA) preferred. 5+ years (7+ preferred) of experience in product management, product marketing, or market analytics at a diagnostics, biotech, or pharmaceutical company. Hematologic oncology experience is strongly preferred, especially multiple myeloma and lymphoma. Working knowledge of oncology molecular testing, next-generation sequencing (NGS), and biomarkers, including NGS bioinformatic workflows (e.g., variant calling, filtering, and interpretation) and genomic data analysis. MRD experience preferred. Experience with data analysis. SQL, Snowflake, or similar tools preferred. Familiarity with a high complexity molecular laboratory, including cfDNA or plasma workflows, is a plus. In depth knowledge of whole genome sequencing and variant types, including structural variants, single nucleotide variants, and phased variants, is preferred. Experience with clinical trials. Experience in IUO and IVD regulated environments is required. Experience bringing a molecular test to market as an LDT, including clinical validation and laboratory requirements. Experience designing or supporting clinical evidence generation, such as clinical validation studies, retrospective studies, or prospective trials. Prior KOL engagement and external customer facing experience preferred. 30-40% travel for advisory boards, congresses, and customer meetings.

Knowledge, Skill, and Abilities: Technical

Understanding of MRD in multiple myeloma and lymphomas, including how blood-based MRD testing fits withing current bone marrow and imaging-based MRD assessment paradigms. Understanding of how somatic variants are detected in whole genome sequencing and how they support MRD tracking in heme tumors. Understanding of LDT market entry requirements and the evidence needed for clinical adoption and payer coverage. Ability to translate customer and clinical needs into clear product requirements. Strong analytical skills. Able to build metrics, interpret data, and present findings. Basic financial modeling skills. Proficiency with MS Excel, Word, and PowerPoint.

Behavioral

Ability to lead without authority and influence cross-functional teams. Strong written and oral communication skills and ability to function effectively in a highly matrixed cross functional environment. Ability to explain complex topics simply (biomarkers, multiple indications, regulatory pathways). Strong customer focus, including building relationships with thought leaders. Strong organization and time management. Able to manage several projects at once and meet tight deadlines. Flexibility bet